Loading organizations...
§ Private Profile · 501 Boylston St, Boston, Massachusetts, 02116, United States
AI-powered SaaS platform providing data analytics for MedTech and pharma, focused on regulatory and post-market data.
Based in Boston, Massachusetts, Basil Systems provides an artificial intelligence SaaS platform that aggregates and analyzes complex regulatory, quality, and clinical data for the medical device and pharmaceutical industries. The company's machine learning technology processes massive global databases, including FDA records, to support medical technology manufacturers and hospitals with product development, supply chain management, post-market surveillance, and compliance strategies. Operating with an estimated 20 to 25 employees, the enterprise generates under $5 million in annual revenue through its B2B subscription model. The startup has secured a total of $17.95 million in venture capital, which includes an $11.5 million Series A funding round completed in March 2026 to accelerate its data analytics capabilities. Basil Systems was originally founded in late 2019 by chief executive officer Trevor Kelly alongside a specialized team of former medical technology executives.
Basil Systems has raised $13.5M across 2 funding rounds.
Basil Systems has raised $13.5M in total across 2 funding rounds.
Basil Systems has raised $13.5M across 2 funding rounds. Most recently, it raised $11.5M Other Equity in April 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 29, 2025 | $11.5M Venture Round | Bert Amato | Argosy Capital, Hearst Ventures | Announced |
| Mar 1, 2021 | $2M Seed | Golden Ventures, Looking Glass Capital | Alumni Ventures | Announced |
Basil Systems has raised $13.5M in total across 2 funding rounds.
Basil Systems's investors include Bert Amato, Argosy Capital, Hearst Ventures, Golden Ventures, Looking Glass Capital, Alumni Ventures.
Basil Systems is a Boston-based technology company founded in 2019 that builds an AI-powered SaaS platform for life sciences organizations, primarily pharmaceutical and MedTech companies.[1][3] Its core product, Basil Intel, leverages the BasilLink dataset—comprising hundreds of millions of indexed documents from global regulatory, clinical, and commercial sources—to deliver actionable intelligence for product lifecycle management, including regulatory strategy, R&D decisions, pharmacovigilance, label expansion, quality management, post-market surveillance, and competitive due diligence.[2][3][4] The platform analyzes imaging, clinical data, and biomarkers to accelerate market entry, mitigate risks, optimize innovation, and improve patient outcomes, serving industry leaders with tools for faster, data-driven decision-making.[1][2]
Basil Systems addresses key pain points in the life sciences sector by consolidating fragmented data into a unified, real-time intelligence layer, enabling sharper strategic choices and revenue gains.[3] It has secured Series A funding, signaling strong growth momentum in a competitive field alongside players like Qureight and GenexAI.[1]
Basil Systems was founded in 2019 in Boston, Massachusetts, at 501 Boylston Street, emerging amid rising demand for AI-driven tools in life sciences to handle exploding volumes of regulatory and clinical data.[1][3] While specific founder details are not publicly detailed in available sources, the company quickly positioned itself as a innovator by building BasilLink, the largest real-time global dataset covering labeling, clinical trials, submissions, adverse events, and guidances.[2] Early traction likely stemmed from its focus on streamlining research for better patient outcomes, with pivotal growth marked by Series A funding and adoption by pharmaceutical leaders for preclinical discovery and pharmacovigilance.[1][2][3]
Basil Systems rides the AI-for-life-sciences wave, capitalizing on the explosion of multimodal data (imaging, biomarkers, clinical trials) amid tightening regulations and faster drug development cycles.[1][2] Timing is ideal as Pharma and MedTech face pressure to cut R&D timelines—often 10-15 years—while navigating global guidances and adverse event monitoring; Basil's platform directly counters this by enabling proactive, data-unified decisions.[3] Market forces like AI adoption in biotech (projected to grow rapidly) and post-pandemic emphasis on pharmacovigilance favor it, positioning Basil as an ecosystem enabler that boosts innovator efficiency and influences standards for data-driven regulatory strategies.[2][4]
Basil Systems is poised for expansion with its Series A backing and leadership in product lifecycle intelligence, likely targeting deeper integrations for emerging areas like personalized medicine and real-world evidence analytics.[1][2] Trends such as multimodal AI advancements and stricter global regs will propel its growth, potentially evolving it into a standard infrastructure layer for life sciences R&D. As data volumes surge, Basil's edge in high-trust, scalable insights could amplify its influence, driving even faster market entries and superior patient impacts—reinforcing its role as a catalyst in AI-powered healthcare innovation.[3][4]